First-in-human study of RO7812653

You may qualify if

• Screening Clinical Dementia Rating Global Score (CDR-GS) of 0.5 or 1.0
• Evidence of AD pathological process, as confirmed by the p-tau 181/Aβ1-42 ratio CSF test or amyloid beta positron emission tomography (Aβ PET)
• Fluency in the language of the tests used at the study site
• Adequate visual and auditory acuity, in the investigator’s judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are permitted)
• If the participant is receiving symptomatic AD medications, a stable dosing regimen for at least 8 weeks prior to screening and until randomisation is required
• Agreement not to participate in other research studies for the duration of this study

You're excluded if

• Any evidence of a condition other than AD that may affect cognition (at the time of screening)
• Presence of any significant cerebral abnormalities that would contraindicate lumbar puncture, as assessed on MRI
• Any other significant cerebral abnormalities that the Investigator considers clinically significant
• History of schizophrenia, schizoaffective disorder, major depression or bipolar disorder
• Impaired coagulation (international normalized ratio [INR] > 1.3 that remains abnormal on retest)
• Uncontrolled hypertension

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2026-01-21